A share price of BridgeBio Pharma Inc [BBIO] is currently trading at $30.14, down -1.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBIO shares have lost -8.72% over the last week, with a monthly amount drifted -4.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $50. On October 03, 2024, Oppenheimer initiated with a Perform rating. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $46 on September 04, 2024. BMO Capital Markets started tracking with a Market Perform rating for this stock on January 31, 2024, and assigned it a price target of $37. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $58 on this stock.
BridgeBio Pharma Inc experienced fluctuations in its stock price throughout the past year between $21.62 and $39.47. Currently, Wall Street analysts expect the stock to reach $45.5 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $30.14 at the most recent close of the market. An investor can expect a potential return of 50.96% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
Trailing Twelve Months sales for BridgeBio Pharma Inc [NASDAQ:BBIO] were 221.90M which represents 237.08% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.66%, Pretax Profit Margin comes in at -2.44%, and Net Profit Margin reading is -2.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is 0.44 and Total Capital is -0.67. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.79 points at the first support level, and at 27.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.13, and for the 2nd resistance point, it is at 34.12.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BridgeBio Pharma Inc [NASDAQ:BBIO] is 4.67. Also, the Quick Ratio is 4.67, while the Cash Ratio stands at 16.48. Considering the valuation of this stock, the price to sales ratio is 25.83.
Transactions by insiders
Recent insider trading involved Ellis Andrea, Director, that happened on Apr 01 ’25 when 30000.0 shares were sold. Director, ANDREA ELLIS completed a deal on Apr 01 ’25 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Kumar Neil sold 75000.0 shares on Mar 25 ’25.
